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108 H.S. Abdel-Ghaffar et al.Results: The time to ﬁrst postoperative analgesic request was signiﬁcantly prolonged in intrave-
nous (318.75 ± 67.37 min) and inﬁltration (214.50 ± 43.06 min) groups compared with placebo
group (66.75 ± 26.95 min). A signiﬁcantly lower mean postoperative VRS scores and signiﬁcantly
reduced 1st day postoperative diclofenac consumption were recorded in iv. group (44.73 ±
9.31 mg), compared with inﬁltration (69.80 ± 38.71 mg) and placebo (87.8 ± 24.40 mg) groups.
An increased intraoperative blood volume losses and intraoperative bleeding complains were
observed in inﬁltration group (34.25 ± 11.93 ml), rather than in iv. (28.85 ± 10.01 ml) and placebo
(24.75 ± 8.70 ml) groups. The (%) of platelet aggregation with ADP, collagen, and arachidonic
acid was signiﬁcantly reduced 15 min and 2 h after study drug administration with highest decreases
in iv. group compared with inﬁltration and placebo groups. No patients reported postoperative
bleeding or GIT adverse effects in the study.
Conclusion: Intraoperative preincisional intravenous lornoxicam enhanced postoperative analgesia
after tonsillectomy in children. In comparison, the analgesic efﬁcacy of locally applied lornoxicam
was inferior to intravenous administration and was associated with increased incidence of intraop-
erative bleeding.
ª 2012 Egyptian Society of Anesthesiologists. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
Postoperative pain is one of the most troublesome aspects after
tonsillectomy. Despite the use of various types of analgesics,
the recovery period can be quite painful. Opioid-based vs.
NSAIDS-based analgesic regimens is still a focus of continu-
ous debate. Non-selective NSAIDS are claimed to cause
increased incidence of perioperative bleeding caused by platelet
function inhibition and gastrointestinal toxicity [1–3].
Although the mechanism of analgesic action (i.e., inhibition
of cyclooxygenase enzyme COX I and II, leading to decreased
prostaglandin synthesis) is the same as all available NSAIDS,
the analgesic efﬁcacy relative to side effects may vary from
agent to agent [4]. When used short term at the lowest effective
dose, NSAIDS may provide for analgesic beneﬁt without
signiﬁcant toxicity [5].
Lornoxicam (Chlorotenoxicam, Xefo) is a potent non-
selective NSAID of the oxicam class with analgesic, anti-
inﬂammatory, and antipyretic properties [6]. It is rapidly
eliminated with a short plasma elimination half life of 3–5 h
[7]. This short plasma half life may in part be responsible for
the lornoxicam’s reduced incidence of adverse effects [7]. We
designed this prospective study to demonstrate the postopera-
tive analgesic efﬁcacy and adverse effects of a single intraoper-
ative dose of lornoxicam 8 mg given before the start of surgery
in tonsillectomy patients (8–18 years). Two routes of adminis-
tration were used in comparison, intravenous vs. peritonsillar
inﬁltration.
2. Patients and methods
This study was approved by the Local Research Ethics Com-
mittee in the Faculty of Medicine, Assiut University, Egypt.
After obtaining an informed written parental consent, 60
ASA physical status I–II patients aged 8–18 years and sched-
uled for elective tonsillectomy due to recurrent or chronic ton-
sillitis were included in the study. Excluded from the study,
patients with known hypersensitivity to medication drugs,
coagulation disorders, thrombocytopenia, bronchial asthma,
signiﬁcant cardiac, renal, pulmonary or hepatic disease, peptic
ulcer, previous peritonsillar abscess formation, active bleeding
for any cause, and patients received any analgesic medicationswithin 24 h preoperative or antiplatelet medication within the
past 2 weeks.
Using an online research randomizer (http://www.random-
izer.org), patients were randomly allocated to three groups of
20 patients each to receive lornoxicam 8 mg iv. (intravenous
group), or peritonsillar inﬁltration (inﬁltration group), or sal-
ine (placebo group), after induction of anesthesia before the
start of the surgery.
The fasted unpremedicated patients received a standardized
anesthetic technique that included induction with propofol 2–
3 mg/kg iv. and atracurium besylate 0.5 mg/kg iv. to facilitate
endotracheal intubation. Anesthesia was maintained with iso-
ﬂurane in oxygen/air mixture. Patients were mechanically ven-
tilated in ventilation parameters that maintain an end-tidal
CO2  32–35 mm Hg. Monitoring included electrocardiogra-
phy (ECG), non-invasive blood pressure, peripheral arterial
oxygen saturation (SaO2%), and end-tidal carbon dioxide
(EtCO2).
After induction of anesthesia before the start of the surgery,
patients in the placebo group received 10 ml of normal saline
iv. and 4 ml saline by peritonsillar inﬁltration (2 ml each side).
The lornoxicam intravenous group patients received iv. 8 mg
lornoxicam diluted to 10 ml plus 4 ml saline by peritonsillar
inﬁltration. The lornoxicam inﬁltration group patients re-
ceived 8 mg lornoxicam diluted to 4 ml and inﬁltrated peri-
capsularly through the tonsillar bed and peritonsillar tissues
in a fanwise direction from the superior to inferior poles of
the fossa (2 ml each side), using a 25-gauge spinal needle over
a syringe, Plus 10 ml saline iv. The attending anesthesiologist,
surgeon and data collection personal were blinded to patient
group assignment and to the nature of the study medication.
Saline 0.9% was used for diluting study drugs, while Lactated
Ringer’s solution was used for ﬂuid maintenance and deﬁcit
replacement.
An intravenous antibiotic and dexamethasone 0.2 mg/kg
were administered. At the end of the surgery, anesthesia was
discontinued and neuromuscular relaxation was reversed using
neostigmine 40 lg/kg and atropine 20 lg/kg slowly intrave-
nous, and patients were turned aside in the recovery position.
Extubation performed awake after the return of protective air-
way reﬂexes. Patients were transported to PACU, where they
discharged to the ward after attaining an Aldrete and Kroulik
Preincisional peritonsillar vs. intravenous lornoxicam for posttonsillectomy analgesia: A clinical 109[8] score >9. Intraoperative blood loss was roughly estimated
by visual estimation of the blood volume lost in suction
bottles, swab counting, and by the surgeon’s estimation of
bleeding using the following scale for perioperative bleeding
assessment (0 = no bleeding, 1 = bleeding as usual, 2 =
bleeding more than usual, 3 = profuse, 4 = excessive, and
lastly 5 = excessive and continuously). Postoperative bleeding
was also assessed by the same scale.
Pain intensity was assessed postoperatively by using the
Verbal Rating scale (VRS) (0 = no pain, 1 = mild pain,
2 = moderate pain, 3 = severe pain, and lastly 4 = excruciat-
ing pain). VRS assessments were performed at rest in the fol-
lowing time points; at arrival to PACU, 30 min, 1, 2, 3, 4, 5,
6, 12, and 24 h postoperative. Diclofenac sodium 1 mg/kg im
was given if requested and if VRS scores wereP2, and the to-
tal consumption of rescue analgesics in the ﬁrst 24 h postoper-
atively was calculated.
Any adverse effects in the 1st 24 h postoperative were trea-
ted and recorded including nausea and vomiting, bleeding, and
any abnormal gastrointestinal manifestations.
Samples were withdrawn from larger veins on the forearm
and antecubital areas in an atraumatic fashion with a mini-
mum of stasis and avoiding contamination with iv ﬂuids.
Platelet counts (·109/lL) and prothrombin time (s) and con-
centration (%) were assessed preoperatively in all patients.
Ten patients from control group, 15 patients from intravenous
group, and 15 patients from the inﬁltration group were ran-
domly selected to perform platelet aggregation studies at the
following timepoints: before, 15 min, 2, and 24 h after the
study medication was administered. Blood (4.5 ml) was with-
drawn on Vacutainer tubes containing 0.5 ml trisodium citrate
3.8% (9:1 ratio) which rapidly centrifuged at 900–1200 rpm for
20 min, and then platelet rich plasma (200–350 · 103/lL) was
taken to estimate platelet aggregation testing.
Platelet aggregation to adenosine diphosphate (ADP)
(10 lM), collagen (2 lg/ml), and arachidonic acid (AA)
(50 lmol/l) was performed using the optical method for the
measurement of platelet aggregation (light transmitter meth-
od). Platelet aggregation was measured by percent change inFigure 1 Platelet aggregometry with adenosine diphosphate, collagen
group).light transmission using the platelet aggregation proﬁler model
PAP-4 (Bio/data corporation) [9], Fig. 1. The reagents were
provided by Chrono-log Company (Havertown, PA, USA).
Values more than 50% were considered normal.
3. Statistical analysis
Analysis was performed using SPSS version 17 (Chicago –
USA). Data were presented as mean ± SD, numbers, frequen-
cies, and percentages. ANOVA followed by post-hoc test was
used for the comparison of parametric data. Kruskal–Wallis
test was used to compare non-parametric data, while Mann–
Whitney used to compare between two groups. Chi-square test
was used for comparison between percentages and frequencies.
P< 0.05 was considered signiﬁcant.
4. Results
Ninety six patients were screened for eligibility to participate in
this study, and 60 patients were subsequently consented and
enrolled (n= 20 per group), with no patient drop outs. All
procedures were performed by 1 of 4 otolaryngologic surgeons
with an even distribution of cases among the four. There were
no signiﬁcant differences among the three groups with respect
to age, gender, weight, ASA class, preoperative prothrombin
time and concentration, preoperative platelet count, operation
time, and anesthesia time (Table 1).
The time to ﬁrst analgesic request was signiﬁcantly pro-
longed in the intravenous group (318.75 ± 67.37 min), com-
pared with the inﬁltration (214.50 ± 43.06 min, P< 0.000)
and the placebo groups (66.75 ± 26.95 min, P< 0.000),
respectively. The total diclofenac consumption in the ﬁrst
24 h postoperative was signiﬁcantly lower in intravenous
group (44.73 ± 9.31 mg), compared with the placebo
(87.8 ± 24.40 mg, P< 0.000) and inﬁltration (69.80 ±
38.71 mg, P< 0.04) groups, with a non-signiﬁcant difference
between the inﬁltration and placebo groups (Table 2). Fig. 2
shows that the mean VRS pain scores recorded at rest in the
intravenous group were signiﬁcantly lower than the mean, and arachidonic acid (an example from lornoxicam intravenous
Table 1 Demographic data.
Placebo Intravenous Inﬁltration P1 P2 P3
Age (year) 12.85 ± 3.09 12.05 ± 3.05 12.45 ± 2.81 NS NS NS
Weight (kg) 33.70 ± 6.19 32.10 ± 6.10 32.90 ± 5.63 NS NS NS
Gender (M/F) 16/4 15/5 14/6 NS NS NS
ASA (I/II) 20/0 20/0 19/1 NS NS NS
Tonsillectomy/adenotonsillctomy 15/5 14/6 16/4 NS NS NS
Preoperative prothrombin time (s) 12.10 ± 0.29 12.33 ± 0.48 12.35 ± 0.52 NS NS NS
Preoperative prothrombin concentration (%) 96.55 ± 3.66 96.15 ± 3.82 95.12 ± 4.12 NS NS NS
Preoperative platelet count (·109/lL) 263.15 ± 62.38 262.15 ± 63.04 254.95 ± 55.83 NS NS NS
Operation time (min) 23.85 ± 5.36 24.10 ± 4.93 25.20 ± 4.17 NS NS NS
Anesthesia time (min) 33.20 ± 4.54 34.65 ± 5.07 34.45 ± 5.28 NS NS NS
Data are presented as mean ± SD and number (n).
P1: Signiﬁcance between placebo and intravenous groups. P2: Signiﬁcance between placebo and inﬁltration groups. P3: Signiﬁcance between
intravenous and inﬁltration groups. NS: non-signiﬁcant.
Table 2 Postoperative pain proﬁle.
Placebo Intravenous Inﬁltration P1 P2 P3
Time to ﬁrst request (min) 66.75 ± 26.95 318.75 ± 67.37 214.50 ± 43.06 0.000 0.000 0.000
Number of rescue analgesia doses
– No request – – – – – –
– One dose – 11 (55%) 8 (40%) 0.000 0.000 0.02
– Two doses 8 (40%) 9 (45%) 3 (15%) NS 0.03 0.002
– Three doses 12 (60%) – 9 (45%) 0.000 NS 0.01
Total diclofenac consumption in 1st 24 h postoperative (mg) 87.8 ± 24.40 44.73 ± 9.31 69.80 ± 38.71 0.000 NS 0.009
Data are presented as mean ± SD, number (n) and frequencies (%).
P1: Signiﬁcance between placebo and intravenous groups. P2: Signiﬁcance between placebo and inﬁltration groups. P3: Signiﬁcance between
intravenous and inﬁltration groups. NS: non-signiﬁcant.
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Figure 2 The verbal rating pain scale in the three studied groups.
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recorded times. Mean VRS pain scores at the 24th hour post-
operative were signiﬁcantly higher in the inﬁltration group
than that of other groups (P< 0.004).The intraoperative blood volume loss was signiﬁcantly
higher in the inﬁltration group (34.25 ± 11.93 ml,
P< 0.007), compared with placebo (24.75 ± 8.70 ml,
P< 0.007) and intravenous (28.85 ± 10.01 ml) groups, with
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trol groups. The surgeons’ estimation of intraoperative bleed-
ing by intraoperative bleeding score showed that the number
of patients exhibited intraoperative bleeding more than usual
was signiﬁcantly higher in the inﬁltration group (9.45%) com-
pared with intravenous (4.20%, P< 0.000) and placebo
(3.15%, P< 0.001) groups, respectively (Table 3).
Intragroup comparison for platelet aggregation with aden-
osine diphosphate (Fig. 3 and Table 4), collagen (Fig. 4 and
Table 5), and arachidonic acid (Fig. 5 and Table 6) showed
that platelet aggregation was signiﬁcantly reduced at 15 min,
2, and 24 h after administration of study drugs in all the stud-
ied groups including the placebo. The highest percentage of de-
crease was observed at 2 h.
Intergroup comparison for platelet aggregation with aden-
osine diphosphate (Fig. 3 and Table 4), collagen (Fig. 4 and
Table 5), and arachidonic acid (Fig. 5 and Table 6) showed
that the highest percentage of reduction in platelet aggregation
was signiﬁcantly observed in the lornoxicam intravenous
group at all the measured timepoints, compared with the inﬁl-
tration and placebo groups. In this study, no patient recorded
a platelet aggregation activity less than 50% with adenosine
diphosphate, collagen, or arachidonic acid.Table 3 Bleeding assessments.
Placebo Intravenou
Intraoperative bleeding score
No bleeding 2 (10%) 2 (10%)
Bleeding as usual 15 (75%) 14 (70%)
Bleeding more than usual 3 (15%) 4 (20%)
Profuse – –
Excessive – –
Excessive and continuous – –
Intraoperative blood loss (ml) 24.75 ± 8.70 28.85 ± 10
Data are presented as mean ± SD, number (n) and frequencies (%).
P1: Signiﬁcance between placebo and intravenous groups. P2: Signiﬁcan
intravenous and inﬁltration groups. NS: non-signiﬁcant.
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Figure 3 The percentages (%) of platelet aggregation with aOf the 60 patients, 9 complained from nausea, 4 of them
vomited once, 1 vomited twice and treated with iv. metclopra-
mide, and 5 complained from excessive secretions with no
intergroup statistical differences. No patients reported abnor-
mal gastrointestinal manifestations, and no patient required
reoperation for recurrent tonsillar bed bleeding.
5. Discussion
The current study had demonstrated that both intravenous
and peritonsillar lornoxicam in a dose of 8 mg administered
intraoperatively before the start of the adenotonsillectomy sur-
gery, enhanced postoperative pain relief, prolonged time to
ﬁrst request, and reduced the need for postoperative analgesia.
Although being better than placebo, the analgesic efﬁcacy of
locally applied lornoxicam was lagging behind that of iv. lorn-
oxicam and was associated with increased intraoperative
bleeding.
Of the panel of NSAIDS tested, lornoxicam was found to
be the most potent balanced inhibitor of human cyclooxygen-
ase (COX)-1/-2. The equipotent COX-isoenzyme inhibition is
complemented by a marked inhibition of interleukin (IL)-6
and of inducible nitric oxide synthetase (iNOS) derived nitrics Inﬁltration P1 P2 P3
3 (15%) NS NS NS
8 (40%) NS 0.03 0.04
9 (45%) NS 0.000 0.001
– – – –
– – – –
– – – –
.01 34.25 ± 11.93 NS 0.007 NS
ce between placebo and inﬁltration groups. P3: Signiﬁcance between
min. 24 hr.after admin
ous group Infiltration group
denosine diphosphate (ADP) in the three studied groups.
020
40
60
80
100
Pl
at
el
et
 A
gg
re
ga
tio
n 
- C
ol
la
ge
n
pre.adm. 15 min. after admin 2hr. after admin. 24hr. after admin
Placebo group Intravenous group Infiltration group
Figure 4 The percentages (%) of platelet aggregation with collagen in the three studied groups.
Table 4 Platlelet aggregation with adenosine diphosphate (ADP).
Placebo Intravenous Inﬁltration P1 P2 P3
ADP 0 (%) 77.50 ± 36.70 92.13 ± 8.56 77.66 ± 8.79 NS NS 0.000
ADP 15 min
(%)
73.40 ± 7.41 (ﬂ5%) 78.86 ± 10.70a (ﬂ14.40%,
P< 0.04)
70.06 ± 6.32 (ﬂ9.78%) NS 0.000 0.01
ADP 2 h
(%)
66.90 ± 2.99a (ﬂ13.67%,
P< 0.04)
50.33 ± 13.52a (ﬂ45.37%,
P< 0.000)
52.86 ± 9.89a (ﬂ31.93%,
P< 0.001)
0.001 0.000 NS
ADP 24 h
(%)
78.10 ± 3.88 (›0.77%) 69.0 ± 8.87a (ﬂ25.10%,
P< 0.03)
59.73 ± 12.02a
(ﬂ23.08%, P< 0.01)
0.005 0.000 0.02
Data are presented as mean ± SD.
ADP0, ADP15 min, ADP2 h, and ADP24 h: % of platelet aggregation with ADP before, and 15 min, 2 h, and 24 h after study drug
administration.
P1: Signiﬁcance between placebo and intravenous groups. P2: Signiﬁcance between placebo and inﬁltration groups. P3: Signiﬁcance between
intravenous and inﬁltration groups. NS: non-signiﬁcant.
a Means statistically signiﬁcant vs. the basal value of the same group.
Table 5 Platlelet aggregation with collagen.
Placebo Intravenous Inﬁltration P1 P2 P3
Collagen 0 (%) 83.25 ± 7.20 83.51 ± 6.8 83.72 ± 5.68 NS NS NS
Collagen
15 min (%)
77.93 ± 4.23 (ﬂ6.39%) 72.41 ± 5.8a (ﬂ13.50%,
P< 0.01)
73.46 ± 4.81a (ﬂ12.03%,
P< 0.03)
0.02 0.01 NS
Collagen 2 h
(%)
53.13 ± 8.2a (ﬂ36.37,
P< 0.001
52.41 ± 11.71a (ﬂ37.04%,
P< 0.001)
56.53 ± 9.72a (ﬂ32.47%,
P< 0.001)
NS NS NS
Collagen 24 h
(%)
72.41 ± 7.92a (ﬂ13.02,
P< 0.04)
70.40 ± 8.56 (ﬂ15.69%,
P< 0.04)
67.60 ± 8.78a (ﬂ19.25%,
P< 0.01)
NS NS NS
Data are presented as mean ± SD.
Collagen 0, collagen 15 min, collagen 2 h, and collagen 24 h: % of platelet aggregation with collagen before, and 15 min, 2 h, and 24 h after
study drug administration.
P1: Signiﬁcance between placebo and intravenous groups. P2: Signiﬁcance between placebo and inﬁltration groups. P3: Signiﬁcance between
intravenous and inﬁltration groups. NS: non-signiﬁcant.
a Means statistically signiﬁcant vs. the basal value of the same group.
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Figure 5 The percentages (%) of platelet aggregation with arachidonic acid (AA) in the three studied groups.
Table 6 Platlelet aggregation with arachidonic acid (AA).
Placebo Intravenous Inﬁltration P1 P2 P3
AA 0 (%) 88.8 ± 9.22 85.26 ± 9.01 82.20 ± 15.60 NS NS NS
AA 15 min
(%)
79.40 ± 15.31a (ﬂ10.58%,
P< 0.03)
77.53 ± 11.45a (ﬂ9.06,
P< 0.04)
75.80 ± 19.00a (ﬂ7.78%,
P< 0.02)
NS NS NS
AA 2 h (%) 62.80 ± 15.41a (ﬂ29.27%,
P< 0.001)
54.13 ± 10.87a (ﬂ36.31%,
P< 0.04)
67.89 ± 22.56a (ﬂ17.40%,
P< 0.001)
NS NS 0.04
AA 24 h
(%)
81.60 ± 9.55 (ﬂ8.10%) 72.53 ± 11.30a (ﬂ14.93%,
P< 0.03
77.53 ± 18.64 (5.68%) 0.048 NS NS
Data are presented as mean ± SD.
AA 0, AA 15 min, AA 2 h, and AA 24 h: % of platelet aggregation with arachidonic acid (AA) before, and 15 min, 2 h, and 24 h after study
drug administration.
P1: Signiﬁcance between placebo and intravenous groups. P2: Signiﬁcance between placebo and inﬁltration groups. P3: Signiﬁcance between
intravenous and inﬁltration groups. NS: non-signiﬁcant.
a Means statistically signiﬁcant vs. the basal value of the same group.
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inﬂammatory and analgesic activities of lornoxicam found in
animal models [11] as well as in clinical studies [3,10,12].
Lornoxicam has been shown to be at least as effective as
comparative NSAIDS and more effective than 10 mg mor-
phine when used at dosesP8 mg to control pain after oral sur-
gery [12]. In addition, oral doses of lornoxicam of 16–24 mg
daily have been more effective than tramadol 300 mg daily in
pain following knee surgery [13]. The clinical trials published
so far mostly comparative clearly document the efﬁcacy of
lornoxicam as a potent analgesic with excellent anti-inﬂamma-
tory properties in a range of painful and/or inﬂammatory con-
ditions including postoperative pain [14] and rheumatoid
arthritis [12]. In accordance with these clinical trials, the anal-
gesic effect of iv. lornoxicam in the current study was clinically
evident by prolonged time to analgesic request, reduced anal-
gesic consumption and lower pain scores in the ﬁrst 24 h
postoperative.
In this study, the selected dose of lornoxicam was based on
several clinical trials that found that a preoperative dose of8 mg was efﬁcient for postoperative analgesia [14–19]. Pediat-
ric doses for iv. lornoxicam ranged from 0.25 to 0.3 mg/kg [20–
22], and as the mean body weight in this study ranged from
32.10 to 33.70 kg, we thought that ﬁxing a dose of 8 mg would
also be beneﬁcial in the age group studied.
The peritonsillar drug inﬁltration had been used success-
fully in previous clinical trials. Drugs given by this route such
as pethidine [23], ketamine [24], tramadol [25], and bupiva-
caine [26] provided a long lasting and satisfactory postopera-
tive analgesia compared with their iv. counterparts and the
placebo. In contrast to these trials, we demonstrated that the
analgesic efﬁcacy of peritonsillar lornoxicam was unsatisfac-
tory. The postoperative pain scores were close to the placebo
group. Moreover, the highest pain score recorded at 24 h post-
operative was in the lornoxicam inﬁltration group.
A recent clinical trial was compared between intravenous
and peritonsillar lornoxicam in adult tonsillectomy and con-
cluded that, preoperative peritonsillar lornoxicam is not supe-
rior to intravenous lornoxicam with comparable intraoperative
blood losses [27]. However, in the current study, we observed
114 H.S. Abdel-Ghaffar et al.an increased intraoperative blood loss in the lornoxicam inﬁl-
tration group. Measures to control bleeding from the tonsillar
bed such as diathermy and surgical suturing were used fre-
quently in patients in the inﬁltration group. Such techniques
are commonly associated with increased postoperative pain
and might be in part responsible for the reduced analgesic efﬁ-
cacy of peritonsillar lornoxicam.
Clinical research studies had demonstrated the analgesic
efﬁcacy of locally applied lornoxicam given; intraarticular
[13], locally administered before lumbar epidural anesthesia
[28] and in intravenous regional anesthesia for hand or fore-
arm surgery [29] with no effect on bleeding. However, for per-
itonsillar administration of lornoxicam, further studies are
needed to investigate the safety and efﬁcacy of such applica-
tion specially in pediatric population.
NSAIDS and perioperative bleeding during tonsillectomy
are still a focus of debate. NSAIDS inhibit cyclooxygenase,
leading to inhibition of platelet thromboxane A2 (TX A2) pro-
duction and platelet aggregation resulting in prolongation of
bleeding time [30]. As platelets play a central role in the coag-
ulation process, some authors believe that NSAIDS should be
contraindicated during tonsillectomy [31,32], while others re-
port that they are a useful and safe addition to postoperative
analgesia, without an increase in perioperative bleeding
[33,34]. Intravenous lornoxicam has been used in adults under-
going hysterectomy [35], major abdominal surgery [14], tonsil-
lectomy [27], and knee arthroscopy [13], without any evidence
of major perioperative bleeding. However, these research trials
were focused on analgesic efﬁcacy and were not powered to de-
tect differences in the frequency of perioperative bleeding.
Moreover, bleeding assessment was done subjectively without
the use of speciﬁc platelet function assessment tests.
The bleeding time which has long been a stable of hemosta-
sis testing has been dropped from the test menu at many lab-
oratories. In its place, tests such as platelet aggregometry,
lumiaggregometry, platelet function analyzer-100, and more
recently ﬂow cytometry are increasingly used to monitor pa-
tients with possible bleeding disorders [36]. Although being
expensive, they allow for quantitative and qualitative assess-
ment of some platelet functions.
In the current study, the percentages of invitro platelet
aggregation triggered by adenosine diphosphate, collagen,
and arachidonic were maximally inhibited 2 h after iv. 8 mg
lornoxicam administration by 45.37%, 37.04%, and 36.31%,
respectively, and nearly returned to baseline values within
24 h postoperative. Felfernig et al., in their study, demon-
strated that a single preoperative dose of 16 mg iv. lornoxicam
signiﬁcantly inhibited platelet aggregation (assessed by whole
blood impedance aggregometry), by 85%, and that inhibition
lasted for at least 8 h after lornoxicam application [37]. An-
other study compared the effect of rofecoxib (a selective
NSAID) and three non-selective NSAIDS; acetylsalicylic acid,
diclofenac, and lornoxicam, on platelet function measured by
CD62 P selectin expression by using ﬂow cytometry. They con-
cluded that platelet function was signiﬁcantly inhibited by ace-
tylsalicylic acid, diclofenac, and lornoxicam but not by
rofecoxib [38].
In this study, ﬁrstly, although maximal platelet inhibition
was observed in intravenous lornoxicam group, complains
from increased intraoperative bleeding were more in the inﬁl-
tration group, suggesting a direct local effect of peritonsillarlornoxicam as a causative factor rather than systemic
absorbtion.
Secondly, the inhibition in platelet aggregation presented in
intravenous group did not result in increased bleeding epi-
sodes. A future research question arises about the relation be-
tween the level of platelet aggregation inhibition and clinical
presentation [39].
Thirdly, patients in the placebo controls showed mild sig-
niﬁcant reductions in platelet functions. This was in contrast
with several previous adult studies that suggested that periop-
erative stress leads to a hypercoagulable state closely related to
the neuroendocrine stress response [40]. This augmentation in
platelet function during stress may be mediated through adren-
ergic activation of a2 receptor subtypes on platelet membrane
[41] or an endocrine-induced increase in platelet cytoplasmic
tyrosine kinase which is responsible for the activation of glyco-
protein IIb–IIIa receptors [40]. In this study, the small sample
size, age group selected, operation type, and the routine intra-
operative administration of iv. dexamethasone might be
responsible for these conﬂicting results.
Therefore, further studies are required to investigate the
safety of lornoxicam in this respect, and lornoxicam should
be avoided for tonsillectomy in patients where increased blood
loss poses a special risk as in hemorrhagic diathesis [7].
In the current study, no patient complained from gastroin-
testinal adverse effects. These results support the facts that
lornoxicam combines the high therapeutic potency of oxicams
with a high tolerability and an improved gastrointestinal tox-
icity proﬁle as compared to the other oxicams [12,42].
In conclusion; the intraoperative preincisional intravenous
lornoxicam administration enhanced postoperative analgesia
after tonsillectomy in children. In comparison, the analgesic
efﬁcacy of locally applied lornoxicam was inferior to the intra-
venous administration and was associated with an increased
incidence of intraoperative bleeding. For conclusive platelet
aggregometry results, a powered large sample sized studies
should be undertaken.
Financial support
Support was provided solely from departmental resources.
References
[1] Castellano P, Lo’pez-Esca’mez JA. American Society of
Anesthesiology classiﬁcation may predict severe post-
tonsillectomy haemorrhage in children. J Otolaryngol
2003;32:302–7.
[2] Krishna S, Hughes LF, Lin SY. Postoperative hemorrhage with
nonsteroidal anti-inﬂammatory drug use after tonsillectomy: a
meta-analysis. Arch Otolaryngol Head Neck Surg
2003;129:1086–9.
[3] Moiniche S, Romsing J, Dahl JB, Trame’r MR. Nonsteroidal
anti-inﬂammatory drugs and the risk of operative site bleeding
after tonsillectomy: a quantitative systemic review. Anesth
Analg 2003;96:68–77.
[4] Souter AJ, Fredman B, White PF. Controversies in the
perioperative use of nonsteroidal anti-inﬂammatory drugs.
Anesth Analg 1994;79:1178–90.
[5] Vadivelu N, Mitra S, Narayan D. Recent advances in
postoperative pain management. Yale J Biol Med
2010;83:11–25.
Preincisional peritonsillar vs. intravenous lornoxicam for posttonsillectomy analgesia: A clinical 115[6] Hitzenberger G, Radhofer-Welte F, Takacs F, Rosenow D.
Pharmacokinetics of lornoxicam in man. Postgrad Med J
1990;66(Suppl. 4):S22–7.
[7] Skjodt NM, Davies NM. Clinical pharmacokinetics of
lornoxicam. A short half-life oxicam. Clin Pharmacokinet
1998;34:421–8.
[8] Aldrete JA, Kroulik D. A postanesthetic recovery score. Anesth
Analg 1970;49:924–34.
[9] Bauer J. Clinical laboratory method. 9th ed. St. Louis: Mosby
Co.; 1982.
[10] Berg J, Fellier H, Christoph T, Grarup J, Stimmeder D. The
analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-
1/-2, inducible nitric oxide synthase (iNOS), and the formation
of interleukin (IL)-6 invitro. Inﬂamm Res 1999;48(7):369–79.
[11] Canduz B, Aktug H, Maviog˘lu O, Erkin Y, Yilmaz O, Uyanikgil
Y, Korkmaz H, Baka M. Epidural lornoxicam administration––
innocent. J Clin Neurosci 2007;14(10):968–74.
[12] Radhofer-Welte S, Rabasseda X. Lornoxicam, a new potent
NSAID with an improved tolerability proﬁle. Drugs Today
(Barc) 2000;36(1):55–76.
[13] Eren M, Koltka K, Ko¨knel Talu G, Asik M, Ozyalcin S.
Comparison of analgesic activity of intraarticular lornoxicam,
bupivacaine and saline after knee arthroscopy. Agri
2008;20(4):17–22.
[14] Karaman Y, Kebapci E, Gurkan A. The preemptive analgesic
effect of lornoxicam in patients undergoing major abdominal
surgery: a randomized controlled study. Int J Surg
2008;6(3):193–6.
[15] Sener M, Yilmazer C, Yilmaz I, et al.. Efﬁcacy of lornoxicam
for acute postoperative pain relief after septoplasty: a
comparison with diclofenac, ketoprofen, and dipyrone. J Clin
Anesth 2008;20:103–8.
[16] Inanoglu K, Gorur S, Akkurt CO, Guven OE, Kararmaz A. The
analgesic efﬁcacy of preoperative versus postoperative
lornoxicam in varicocele repair. J Clin Anesth 2007;19:587–90.
[17] Sapolya O, Karamanhoglu B, Memis D. Analgesic effects of
lornoxicam after total abdominal hysterectomy. J Opioid
Manage 2007;3:155–9.
[18] Sener M, Yilmazer C, Yilmaz I, Caliskan E, Donmez A, Arslan
G. Patient-controlled analgesia with lornoxicam vs. dipyrone for
acute postoperative pain relief after septorhinoplasty: a
prospective, randomized, double-blind, placebo-controlled
study. Eur J Anaesthesiol 2008;25:177–82.
[19] Isik B, Arslan M, O¨zsoylar o¨, Akcabay M. Preoperative
lornoxicam versus tramadol on postoperative pain and adverse
effects in adult tonsillectomy. Agri 2009;21:113–20.
[20] Verghese ST, Hannallah RS. Acute pain management in
children. J Pain Res 2010;15(3):105–23.
[21] Li Xiuzel, Tan Ling. A comparison of analgesic efﬁcacy and
safety of tramadol and lornoxicam for postoperative pain relief
in children. Sichaun Med J; 2007-07.
[22] Fu Yuezhen, Jin Quanying, Gu Zhiqing. Clinical observation of
postoperative patient controlled intravenous analgesia in 612
children. J Pract Diag Ther; 2007-11.
[23] Nikandish R, Maghsoodi B, Khademi S, Motazedian S,
Kaboodkhani R. Peritonsillar inﬁlteration with bupivacaine
and pethidine for relief of posttonsillectomy pain: a randomized
double-blind study. Anaesthesia 2008;63(1):20–5.
[24] Honarmand A, Safavi MR, Jamshidi M. The preventive
analgesic effect of preincisional peritonsillar inﬁlteration of
two low doses of ketamine for postoperative pain relief in
children following adenotonsillectomy. Paediatr Anaesth
2008;18(6):508–14.
[25] Ugur MB, Yilmaz M, Altunkaya H, Cinar F, Ozer Y, Beder L.
Effects of intramuscular and peritonsillar injection of tramadol
before tonsillectomy: a double blind, randomized, placebo-controlled clinical trial. Int J Ped Otorhinolaryngol
2008;72:241–8.
[26] Orntoft S, Longreen A, Moiniche S, Dhal JB. A comparison of
pre- and postoperative tonsillar inﬁlteration with bupivacaine on
pain after tonsillectomy. A pre-emptive effect? Anaesthesia
1994;49(2):151–4.
[27] Ismail SA, Mowaﬁ HA. Preoperative peritonsillar lornoxicam
inﬁlteration is not superior to intravenous lornoxicam for pain
relief following tonsillectomy in adults. Eur J Anesthesiol
2010;27(9):807–11.
[28] Muslu B, Usta B, Muslu S, Yesilay A, Go¨zdemir M, Sert H,
Demirciglu R. Effect of locally administered lornoxicam in the
management of low back pain after lumbar epidural anesthesia:
a double-blind, randomized, controlled study. Minerva
Anestesiol 2009;75(9):494–7.
[29] Kol IO, Ozturk H, Kaygusuz K, Gursoy S, Comert B,
Mimaroglu C. Addition of dexmedetomidine or lornoxicam to
prilocaine in intravenous regional anesthesia for hand or
forearm surgery: a randomized controlled study. Clin Drug
Investig 2009;29(2):121–9.
[30] Power I, Chambers WA, Greer IA, Ramage D, Simon E.
Platelet function after intramuscular diclofenac. Anaesthesia
1990;45:916–9.
[31] Splinter WM, Rhine EJ, Roberts DW, Reid CW, MacNeill HB.
Preoperative ketorlac increases bleeding after tonsillectomy in
children. Can J Anaesth 1996;43:560–3.
[32] Schmidt A, Bjo¨rkman S, Akeson J. Preoperative rectal versus
paracetamol for tonsillectomy: effects on pain and blood loss.
Acta Anaesthesiol Scand 2001;45:48–52.
[33] Jeyakumar A, Brickman TM, Williamson ME, et al.
Nonsteroidal anti-inﬂammatory drugs and postoperative
bleeding following adenotonsillectomy in pediatric patients.
Arch Otolaryngol Head Neck Surg 2008;134:24–7.
[34] Mckean SA, Lee MS, Hussain SS. Comparative study of
posttonsillectomy hemorrhage with the use of diclofenac
versus dihydrocodeine for postoperative analgesia and review
of the literature. J Otolaryngol Head Neck Surg 2008;37:577–81.
[35] Gong ZY, Ye TH, Qin XT, Yu GX, Guo XY, Luo AL. Patient-
controlled analgesia with lornoxicam in patients undergoing
gynecological surgery. Ke Xue Yuan Xue Bao 2001;23(5):472–5.
[36] Zeidan AM, Kouides PA, Tara MA, Fricke WA. Platelet
function testing: state of the art. Expert Rev Cardiovasc Ther
2007;5(5):955–67.
[37] Felfernig M, Salat A, Kimberger O, Gradisek P, Miller MR,
Felfernig D. Preemptive analgesia by lornoxicam- an NSAID-
signiﬁcantly inhibits perioperative platelet aggregation. Eur J
Anaesthesiol 2008;25(9):726–31.
[38] Blaicher AM, Landsteiner HT, Al-Falaki O, Zwerina J, Volf I,
Gruber D, Zimpfer M, Hoerauf K. Acetylsalicylic acid,
diclofenac, and lornoxicam, but not rofecoxib affect platelet
CD 62 P expression. Anesth Analg 2004;98(4):1082–5.
[39] Harrington RA, Kliman NS, Granger CB, Ohman EM,
Berkowitz SD. Relation between inhibition of platelet
aggregation and clinical outcome. Am Heart J 1998;136(4 pt 2
su):s43–50.
[40] Rosenfeld BA, Faraday N, Campbell D, et al. Hemostatic
effects of stress hormone infusion. Anesthesiology
1994;81:116–26.
[41] Rosenfeld BA, Faraday N, Campbell D, et al. Perioperative
platelet reactivity and the effects of clonidine. Anesthesiology
1993;79:255–61.
[42] Rawal N, Kroner K, Simin-Geertsen M, Hejl C, Likar R. Safety
of lornoxicam in the treatment of postoperative pain: a post-
marketing study of analgesic regimens containing lornoxicam
compared with standard analgesic treatment in 3752 day-case
surgery patients. Clin Drug Investig 2010;30(10):687–97.
